Emkay Pharmaceuticals (M Cure) expects its net debt to EBITDA ratio to improve in the medium term due to strong cash flow and appropriate capital spending management.
"M Cure expects this ratio to improve in the medium term as it expects its cash flow to remain strong and will be able to manage cautious capital spending appropriately."
